Grace & White’s Northwest Biotherapeutics NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-14,705
Closed -$9.19K – 150
2023
Q1
$9.19K Hold
14,705
– – ﹤0.01% 137
2022
Q4
$11.5K Hold
14,705
– – ﹤0.01% 129
2022
Q3
$10K Sell
14,705
-10,600
-42% -$7.21K ﹤0.01% 129
2022
Q2
$16K Hold
25,305
– – ﹤0.01% 129
2022
Q1
$18K Hold
25,305
– – ﹤0.01% 130
2021
Q4
$18K Hold
25,305
– – ﹤0.01% 131
2021
Q3
$32K Hold
25,305
– – 0.01% 131
2021
Q2
$37K Hold
25,305
– – 0.01% 128
2021
Q1
$38K Buy
25,305
+14,705
+139% +$22.1K 0.01% 126
2020
Q4
$16K Buy
+10,600
New +$16K ﹤0.01% 126

Other funds holding NWBO

Grace & White's NWBO Position: Q2 2023 in Review

Grace & White sold out of Northwest Biotherapeutics (NWBO) in Q2 2023, closing a stake of 14,705 shares — an estimated $9.19K sold.

Grace & White first reported a position in NWBO in Q4 2020 and held it in 10 quarters. The position peaked at $38K in Q1 2021. 11 funds tracked by Wall St. Rank hold NWBO as of Q2 2023.

  • Grace & White reported no remaining Northwest Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Grace & White sold 14,705 Northwest Biotherapeutics shares in Q2 2023, an estimated $9.19K.
  • Grace & White first reported a position in Northwest Biotherapeutics in Q4 2020 and held it in 10 quarters.
  • Grace & White's Northwest Biotherapeutics position peaked at $38K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Northwest Biotherapeutics as of Q2 2023.

Based on Grace & White's 13F filing for Q2 2023, filed 26 Jul 2023.